Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.
Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ.
Joseph RW, et al. Among authors: parker a.
J Immunother. 2012 Nov-Dec;35(9):711-5. doi: 10.1097/CJI.0b013e3182742c27.
J Immunother. 2012.
PMID: 23090080